# Sotyktu (deucravacitinib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/deucravacitinib

> The FDA approved Sotyktu (deucravacitinib), sponsored by BRISTOL MYERS SQUIBB CO (BMY), on September 9, 2022 for to treat moderate-to-severe plaque psoriasis.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Sotyktu (deucravacitinib) FDA approved?

Yes. The FDA approved Sotyktu (deucravacitinib), sponsored by BRISTOL MYERS SQUIBB CO (BMY), on September 9, 2022 for to treat moderate-to-severe plaque psoriasis. FDA novel drug approvals: "Sotyktu | deucravacitinib | 9/9/2022 | To treat moderate-to-severe plaque psoriasisDrug Trials Snapshot" [Calendar and source filings](https://sec-api.dev/pdufa/deucravacitinib)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/deucravacitinib#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Sotyktu (deucravacitinib) |
| Codes | BMS-986165 |
| Sponsor | BRISTOL MYERS SQUIBB CO (BMY) https://sec-api.dev/companies/bmy/catalysts |
| Indications | To treat moderate-to-severe plaque psoriasis, [Psoriasis](https://sec-api.dev/indications/psoriasis), [Systemic Lupus Erythematosus](https://sec-api.dev/indications/systemic-lupus-erythematosus), [Juvenile Psoriatic Arthritis](https://sec-api.dev/indications/juvenile-psoriatic-arthritis), [Sjögren's Syndrome](https://sec-api.dev/indications/sjogren-s-syndrome), [Plaque Psoriasis](https://sec-api.dev/indications/plaque-psoriasis) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### September 9, 2022: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To treat moderate-to-severe plaque psoriasis.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Sotyktu | deucravacitinib | 9/9/2022 | To treat moderate-to-severe plaque psoriasisDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022
- openFDA Drugs@FDA: "NDA214958 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20220909, review_priority STANDARD; sponsor_name BRISTOL; product SOTYKTU (DEUCRAVACITINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214958%22

### March 6, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA214958 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20260306, review_priority STANDARD; sponsor_name BRISTOL; product SOTYKTU (DEUCRAVACITINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214958%22

### July 21, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Psoriasis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04036435 (Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-21 (ACTUAL); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT04036435

### Oct 2026 to Jan 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Systemic Lupus Erythematosus.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05617677 (A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-19 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT05617677

### Oct 2026 to Jan 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Systemic Lupus Erythematosus.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05620407 (A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-19 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT05620407

### October 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 3. Indication: Systemic Lupus Erythematosus.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05617677 (A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-19 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT05617677

### October 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 3. Indication: Systemic Lupus Erythematosus.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05620407 (A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-19 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT05620407

### Nov 2026 to Feb 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Sjögren's Syndrome.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05946941 (A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-18 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT05946941

### November 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Sjögren's Syndrome.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05946941 (A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-18 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT05946941

### January 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Plaque Psoriasis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04772079 (A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-01 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT04772079

### Jan to Apr 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Plaque Psoriasis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04772079 (A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-01 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT04772079

### Oct 2029 to Jan 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Plaque Psoriasis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06979453 (A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-10-12 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT06979453

### October 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Plaque Psoriasis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06979453 (A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-10-12 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT06979453

### Mar to Jun 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Juvenile Psoriatic Arthritis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06869551 (A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-03-06 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT06869551

### March 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Juvenile Psoriatic Arthritis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06869551 (A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-03-06 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT06869551

### Oct 2030 to Jan 2031: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Systemic Lupus Erythematosus; Sjögren's Disease; Psoriasis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07791199 (Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-10-31 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT07791199

### October 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Systemic Lupus Erythematosus; Sjögren's Disease; Psoriasis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07791199 (Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-10-31 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." https://clinicaltrials.gov/study/NCT07791199

## Same indication

- [AMJEVITA® (adalimumab)](https://sec-api.dev/pdufa/adalimumab) (ABBV)
- [Saphnelo (anifrolumab)](https://sec-api.dev/pdufa/anifrolumab) (AZN)
- [Anifrolumab + apfs](https://sec-api.dev/pdufa/anifrolumab-apfs) (AZN)
- [Otezla (apremilast)](https://sec-api.dev/pdufa/apremilast) (AMGN)
- [BLINCYTO® (blinatumomab)](https://sec-api.dev/pdufa/blinatumomab) (AMGN)
- [Cadefrecitinib](https://sec-api.dev/pdufa/cadefrecitinib) (LKFT)
- [Dazodalibep](https://sec-api.dev/pdufa/dazodalibep) (AMGN)
- [Envudeucitinib](https://sec-api.dev/pdufa/envudeucitinib) (ALMS)
- [Tremfya (guselkumab)](https://sec-api.dev/pdufa/guselkumab) (JNJ)
- [Hypericin](https://sec-api.dev/pdufa/hypericin) (SNGX)
- [Ianalumab](https://sec-api.dev/pdufa/ianalumab) (NVS)
- [Taltz (ixekizumab)](https://sec-api.dev/pdufa/ixekizumab) (LLY)
- [MEDI-546](https://sec-api.dev/pdufa/medi-546) (AZN)
- [MK-6194](https://sec-api.dev/pdufa/mk-6194) (MRK)
- [Obexelimab](https://sec-api.dev/pdufa/obexelimab) (ZBIO)
- [Open-label envudeucitinib](https://sec-api.dev/pdufa/open-label-envudeucitinib) (ALMS)
- [ORKA-001](https://sec-api.dev/pdufa/orka-001) (ORKA)
- [Orka-001 induction dose](https://sec-api.dev/pdufa/orka-001-induction-dose) (ORKA)
- [ORKA-002](https://sec-api.dev/pdufa/orka-002) (ORKA)
- [Piclidenoson](https://sec-api.dev/pdufa/piclidenoson) (CANF)
- [Skyrizi® (risankizumab)](https://sec-api.dev/pdufa/risankizumab) (ABBV)
- [Sar441344 iv](https://sec-api.dev/pdufa/sar441344-iv) (SNY)
- [TAK-279](https://sec-api.dev/pdufa/tak-279) (TAK)
- [Tapinarof cream, 1%](https://sec-api.dev/pdufa/tapinarof-cream-1) (OGN)
- [RINVOQ® (upadacitinib)](https://sec-api.dev/pdufa/upadacitinib) (ABBV)
- [WEZLANA® (ustekinumab)](https://sec-api.dev/pdufa/ustekinumab) (JNJ)
- [Zasocitinib](https://sec-api.dev/pdufa/zasocitinib) (TAK)
- [Zl-1102 1% w/w gel bid for 16 weeks](https://sec-api.dev/pdufa/zl-1102-1-w-w-gel-bid-for-16-weeks) (ZLAB)

Calendar months: [October 2026](https://sec-api.dev/fda-calendar/2026-10), [November 2026](https://sec-api.dev/fda-calendar/2026-11)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/deucravacitinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Sotyktu (deucravacitinib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/deucravacitinib

```bibtex
@misc{secapidev_pdufa_deucravacitinib_20261116,
  title        = {Sotyktu (deucravacitinib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/deucravacitinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_deucravacitinib_20261116","title":"Sotyktu (deucravacitinib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/deucravacitinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
